X

Trial Profile

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tremelimumab (Primary)
Indications Malignant-mesothelioma; Mesothelioma
Focus Therapeutic Use
Acronyms DETERMINE
Sponsors AstraZeneca; MedImmune

Most Recent Events

30 Aug 2024 Planned End Date changed from 31 Dec 2024 to 24 Apr 2025.
17 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
18 Jan 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com